Summit Trail Advisors LLC Acquires New Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Summit Trail Advisors LLC acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 16,428 shares of the company’s stock, valued at approximately $199,000.

Several other hedge funds have also recently bought and sold shares of ELAN. AM Squared Ltd bought a new stake in shares of Elanco Animal Health during the 3rd quarter worth about $34,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health during the 3rd quarter worth about $35,000. Farther Finance Advisors LLC raised its position in shares of Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after buying an additional 2,044 shares in the last quarter. Venturi Wealth Management LLC raised its position in shares of Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after buying an additional 1,601 shares in the last quarter. Finally, Blue Trust Inc. raised its position in shares of Elanco Animal Health by 2,129.2% during the 3rd quarter. Blue Trust Inc. now owns 3,968 shares of the company’s stock worth $57,000 after buying an additional 3,790 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Barclays boosted their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Stifel Nicolaus lowered their price objective on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, UBS Group initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $16.29.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $11.65 on Friday. The firm’s 50 day moving average is $11.96 and its 200-day moving average is $13.16. The stock has a market capitalization of $5.76 billion, a P/E ratio of 29.11, a P/E/G ratio of 2.69 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 12-month low of $11.11 and a 12-month high of $18.80.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.